Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

941

HTML

6316

Tables (1-4)

445

Sum=7702

Feb 12, 2012 (publication date) through Sep 20, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines For Clinical Practice

World J Virol . Feb 12, 2012; 1(1): 23-30
Published online Feb 12, 2012. doi: 10.5501/wjv.v1.i1.23

Table 4 Alternative PRRS vaccines

	Encoded ORF/GP	Immunogenicity		Protection		Ref.
		Antibody	CMI	Homologous	Heterologous
DNA vaccine	ORF1-7	+	+	+	ND	[45,46]
Subunit vaccine	GP5	Poor	Poor	-	ND	[47,48]
Synthetic peptide vaccine	GP5	-	-	ND	-	[13]
Adenovirus vector vaccine	GP3, 4, 5	+	+	ND	ND	[49-51]
PRV vector vaccine	GP5, M	+	+	+	ND	[52,53]
Poxvirus vector vaccine	GP3, 5, M	+	+	+	ND	[54,55]
TGEV vector vaccine	GP5, M	+	ND	+	ND	[56]
Alphavirus-derived replicon	GP5, M	+	+	+	+	[57]
Bacterial vector vaccine	GP5, M	+	-	+	ND	[58]
Insect cell-derived vaccine	ORF3, 5, 7	+	ND	+	ND	[59]
Plant-derived vaccine	GP5	+	+	ND	ND	[60,61]
Gene-deleted MLV (deleted15-mer nsp2 epitope)		+	ND	ND	ND	[65]

+: Success; -: Failure; ND: Not determined.

Citation: Charerntantanakul W. Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects. World J Virol 2012; 1(1): 23-30
URL: https://www.wjgnet.com/2220-3249/full/v1/i1/23.htm
DOI: https://dx.doi.org/10.5501/wjv.v1.i1.23